Calcium Gluconate Dosing for Hyperkalemia
For hyperkalemia with cardiac toxicity or ECG changes, administer 15 to 30 mL of 10% calcium gluconate IV over 2 to 5 minutes 1.
Administration Protocol
The American Heart Association 2010 ACLS guidelines provide clear dosing parameters for calcium gluconate in hyperkalemia management 1:
- Dose: 15 to 30 mL of 10% calcium gluconate solution
- Route: Intravenous
- Rate: Administer over 2 to 5 minutes
- Alternative: Calcium chloride (10%) 5 to 10 mL (500 to 1000 mg) IV over 2 to 5 minutes can be used, though calcium gluconate is preferred in most settings
Mechanism and Timing
Calcium gluconate works by stabilizing the myocardial cell membrane, antagonizing the effects of potassium on cardiac excitable tissue 1. This action occurs rapidly—within 1 to 3 minutes—making it the first-line intervention for cardioprotection in severe hyperkalemia 2. Critically, calcium does not lower serum potassium levels; it only protects the heart temporarily 2.
When to Administer
Calcium gluconate is indicated when hyperkalemia presents with:
- ECG changes: Peaked T waves, prolonged PR interval, widened QRS complex, flattened P waves, or sine-wave pattern 1
- Severe hyperkalemia: Potassium >6.5 mEq/L with cardiac manifestations 1
- Cardiac arrest secondary to hyperkalemia 1
Repeat Dosing
If no effect is observed within 5 to 10 minutes, repeat the dose 2. The effect of calcium is temporary, lasting only while membrane stabilization is needed during the acute phase.
Special Considerations for Your Patient
In a patient with congestive heart failure and impaired renal function:
Monitoring Requirements
- Continuous ECG monitoring during administration 3
- Monitor heart rate; stop injection if symptomatic bradycardia occurs 4
- For renal impairment, initiate at the lowest dose of the recommended range and monitor serum calcium levels every 4 hours 3
Administration Route
- Central venous access is preferred when available 4, 5
- If using peripheral IV, ensure secure access as extravasation can cause severe tissue injury 4
- Calcium chloride causes more severe tissue damage with extravasation; calcium gluconate is safer for peripheral administration 4
Concurrent Therapy Considerations
- Do not mix calcium gluconate with sodium bicarbonate or vasoactive amines 4
- Flush lines thoroughly between medications
- In patients on digoxin (common in CHF), calcium administration requires extra caution as it may precipitate digoxin toxicity
Complete Hyperkalemia Management Algorithm
Calcium gluconate is only the first step in a sequential treatment approach 1, 2:
Step 1: Membrane Stabilization (Immediate)
- Calcium gluconate 15-30 mL IV over 2-5 minutes
Step 2: Shift Potassium Intracellularly (Within 30 minutes)
- Insulin + glucose: 10 units regular insulin with 25g glucose (50 mL D50) IV over 15-30 minutes 1
- Nebulized albuterol: 10-20 mg over 15 minutes 1
- Sodium bicarbonate: 50 mEq IV over 5 minutes (only if concurrent metabolic acidosis) 1
Step 3: Remove Potassium from Body
- Diuretics: Furosemide 40-80 mg IV (if patient has residual renal function and is hypervolemic) 1
- Hemodialysis: For refractory cases or oliguric renal failure 1, 2
- Potassium binders: Newer agents (patiromer, sodium zirconium cyclosilicate) for chronic management 2, 6
Critical Pitfalls to Avoid
Do not delay calcium administration while waiting for other therapies—it provides immediate cardioprotection 2
Do not use calcium gluconate alone—it does not lower potassium levels and must be followed by potassium-shifting and elimination strategies 2, 7
Do not discontinue RAAS inhibitors prematurely in CHF patients after hyperkalemia resolves—these are life-saving medications that should be continued with appropriate potassium management 6, 8, 9
Avoid calcium chloride in peripheral lines when calcium gluconate is available—gluconate is safer for peripheral administration 4
Monitor for hypercalcemia in patients with renal impairment, as calcium excretion is impaired 3